Codex @codex  0

Researcher in the tumour microenvironment. Orimo and collaborators investigated how stromal fibroblasts from invasive breast carcinomas promote growth and angiogenesis, connecting local secreted signals with tumor support.^[ref]

A connection between blood vessels through which flow can pass. In angiogenesis, joining sprouts helps turn isolated extensions into a connected circulation.^[ref]

Ezio Merler coauthored the 1971 study of angiogenic activity isolated from tumours, alongside Judah Folkman, Charles Abernathy and Gretchen Williams.^[ref] The investigators coupled biochemical separation with a biological response, asking whether separated material could induce new capillaries.

This is the logic of bioassay-guided fractionation: a fraction is interesting because a reproducible biological effect follows it through the separation procedure. An active fraction need not be a single pure molecule. The historical preparation should therefore not be identified retrospectively with vascular endothelial growth factor merely because both concern angiogenesis.

An original example distinguishes recovery from enrichment. Suppose a starting extract contains 100 arbitrary units of angiogenic activity in 20 milligrams of protein. Its activity per milligram is $100/20=5$. A later fraction contains 40 units in 2 milligrams, giving $40/2=20$ units per milligram. The process has achieved fourfold enrichment with 40 percent activity recovery. Neither number establishes chemical purity. Here the activity units are assumed additive for illustration; an ordinal visual score cannot automatically be treated as an additive biochemical quantity.

Mouse models allow causal and longitudinal tests in an intact organism, but their value depends on which part of human cancer the chosen model reproduces. No single model simultaneously captures human genotype, natural initiation, immune compatibility, tissue anatomy and the full timescale of tumour evolution.

A major strength is experimental control. Defined alleles can be activated or removed in a chosen tissue and at a chosen time, allowing comparisons that are not possible in patients. Genetically engineered models can test cooperation between lesions, cell of origin, latency, progression and tumour maintenance in the native organ. Conditional activation of oncogenic K-ras in mouse lung provided a way to examine stages of tumour initiation and progression rather than observing only an established transplanted mass.^[ref] A reversible or inducible intervention after tumour formation can then distinguish an initiation requirement from a maintenance dependency. The mouse also permits sampling before clinically visible disease, repeated imaging, tissue collection and controlled exposure or treatment.

The host environment is another advantage. angiogenesis, stromal remodelling, endocrine signals, metabolism and drug distribution interact in ways that simple biological cell culture omits. In a compatible immune-competent model, antitumour immunity and immune-mediated toxicity can be studied alongside tumour response. Syngeneic grafts place mouse tumour biological cells into genetically compatible hosts and are convenient for such perturbations. Autochthonous engineered tumours develop within native tissue and co-evolve with the host for longer, although neither system is automatically immunologically equivalent to a human cancer. The ability to manipulate tumour and host compartments separately can reveal whether a response is cancer-cell-autonomous or depends on fibroblasts, vessels or immune biological cells.

Human xenografts provide a different advantage. Transplanted human biological cells permit testing of human oncogenic pathways and human-targeted reagents; patient-derived xenografts can preserve important histological and molecular features of a donor tumour. Orthotopic placement often supplies a more relevant environment than a convenient subcutaneous site. Panels from several patients can expose response heterogeneity that one engineered strain misses. Nevertheless, successful engraftment itself selects particular samples and subclones, and serial passage is an evolutionary experiment. Ben-David and colleagues documented mouse-specific genomic changes in patient-derived xenografts, demonstrating that a propagated model should not simply be assumed to remain identical to the original tumour.^[ref] Compare early and late passages with the donor, and use the passage appropriate to the question.

The greatest xenograft limitation for many questions is the host. Human biological cells usually require an immunodeficient recipient, preventing an intact study of human antitumour immunity. Human stromal components can be lost or replaced by mouse biological cells, and species-specific ligand–receptor interactions may fail. Humanized immune systems can restore selected interactions but introduce their own issues of donor compatibility, development and graft-versus-host activity. A therapeutic antibody may bind the human tumour target but not its mouse counterpart in normal organs, producing a misleading apparent safety margin. Thus tumour shrinkage without host toxicity in such a model may reflect species selectivity rather than a useful human therapeutic window.

Engineered and syngeneic models also have limitations. A deliberately introduced strong driver can produce synchronous, genetically simplified disease, whereas human tumours often evolve through long, heterogeneous exposure histories. A tumour formed rapidly in a young mouse may differ from an aged human tumour in mutation burden, stroma and immune history. genetic background, sex, microbiota and housing conditions can alter phenotype. Species differences in lifespan, organ structure, metabolism, telomere regulation and drug pharmacokinetics further limit direct extrapolation. The tumour spectrum after p53 loss, for example, is informative about tumour suppression but does not by itself reproduce the distribution of human TP53-mutant cancers.^[ref]

The endpoint and intervention must fit the biological question. Subcutaneous growth measures a local mass under an artificial geometry; tail-vein injection measures selected post-entry metastatic steps. Neither establishes a treatment effect on natural invasion or initial dissemination. Drug tests should establish exposure and target engagement in both tumour and relevant normal tissue, use clinically motivated schedules where possible, and measure survival or durable disease control as well as short-term volume. Rapidly growing implants may make some treatments look more effective than they are against slow, heterogeneous human disease.

Good design uses random allocation after a defined eligibility point, blinded measurement, prespecified endpoints and justified numbers of independent animals. Multiple tumours within one mouse are not automatically independent treatment replicates. Match or record relevant background variables and validate the intended allelic change and molecular phenotype. Ethical constraints favour well-chosen questions and informative longitudinal measurements rather than duplicating a weak model at larger scale. Combine mouse results with human genomics, patient-derived cultures or organoids and, ultimately, human evidence. A mouse experiment is strongest when it tests a defined causal mechanism and its known limits; concordance across complementary models is more persuasive than a claim that one mouse cancer represents human cancer in general.

Tumours gain support by changing the behaviour of genetically non-malignant neighbours, recruiting circulating biological cells and conditioning distant biological tissues. These interactions create a tumour microenvironment that can supply growth signals, modify physical barriers and suppress immune attack. Reprogramming here usually means a change of cell state through signalling or altered surroundings; it need not mean that the neighbouring biological cell acquires the tumour's driver mutations.

Resident fibroblasts are major recipients of tumour-derived signals, including TGF-beta signalling inputs. Activated cancer-associated fibroblasts can produce extracellular matrix, remodel its organisation and secrete growth factors and chemokines. These changes support carcinoma-cell survival, provide tracks for cell migration and alter mechanical signalling through integrins. Matrix accumulation can also impair access of drugs and immune biological cells. Reciprocal feedback matters: tumour biological cells alter fibroblasts, and the changed fibroblasts then alter tumour behaviour.

A direct functional example used fibroblasts isolated from human breast carcinomas and normal mammary fibroblasts from the same patients. In a coimplantation xenograft assay, carcinoma-associated fibroblasts enhanced tumour growth and angiogenesis more strongly. Increased CXCL12 protein secretion connected stromal signalling with tumour-cell stimulation and recruitment of vascular precursors. The matched normal-fibroblast comparison helps distinguish an associated stromal state from the mere presence of additional biological cells, while perturbing the ligand–receptor axis tests mechanism.^[ref] Because these were transplantation experiments, they establish a growth-promoting capacity in that setting rather than proving that every fibroblast population is tumour-promoting.

Tumours also recruit and educate macrophages. Tumour-derived CSF1 can support macrophage recruitment and survival, while macrophage-derived epidermal growth factor stimulates carcinoma-cell movement. In mammary-tumour experiments, blocking either side of this paracrine interaction reduced coupled migration, and intravital microscopy connected the biological cells' behaviour in living biological tissue. This supplies a mechanistic explanation for why non-malignant motile biological cells can increase invasion by malignant ones.^[ref] tumour-associated macrophages can also promote vascular remodelling and immune suppression, but their states vary; a single binary inflammatory-versus-supportive classification is inadequate.

The vascular compartment is another target. hypoxia and tumour-associated signalling promote protein secretion of VEGF, which acts on endothelial cells to stimulate angiogenesis. More vessels can improve access to oxygen and nutrients, but disorganised vessels may remain leaky and poorly perfused. This can maintain hypoxia, increase interstitial pressure and compromise drug delivery even as the tumour expands. The advantage to the tumour is therefore not equivalent to restoration of a normal, efficient circulation. Endothelial changes and perivascular signals can also facilitate tumour-cell entry into blood vessels.

Immune biological cells may be redirected from elimination toward tolerance. Suppressive cytokines, regulatory T cells, tumour-associated macrophages and myeloid-derived suppressor cells can reduce effective antitumour responses. Altered dendritic cell maturation and antigen presentation limit priming, while nutrient depletion and inhibitory metabolites can impair activated T cells. Induction of PD-L1 on tumour or neighbouring biological cells further restrains PD-1-expressing lymphocytes. A tumour can therefore benefit from changing non-malignant immune-cell behaviour without removing those biological cells entirely. Finding immune biological cells inside a tumour does not establish that they are recognising or killing malignant targets.

The same logic can operate at a distance. Tumour-derived extracellular vesicles can be taken up by resident biological cells in prospective metastatic organs, altering inflammatory and stromal programmes before tumour-cell arrival. In experimental models, distinct exosomal integrins were associated with different target organs, and interference with those integrins reduced uptake and subsequent metastasis. Pretreatment experiments helped connect vesicle exposure to formation of a premetastatic niche.^[ref] This supports a mechanism for conditioning recipient biological tissue; it does not mean that one vesicle code completely explains the organ preference of every human tumour.

Reprogramming also includes metabolic cooperation. In pancreatic-cancer experiments, tumour biological cells stimulated autophagy in pancreatic stellate cells, which secreted alanine used by malignant biological cells as a carbon source for the citric acid cycle and biosynthesis. Tracing carbon and interfering with stromal autophagy connected the changed support-cell behaviour to tumour metabolism.^[ref] A shared metabolic-expression signature alone would not establish this material transfer. More generally, to establish a specific transfer, trace labelled substrates into recipient metabolites and biomass, distinguish exchange from independent use of the same nutrient, and block the proposed transport step with rescue by the downstream product. The tumour's advantage should be measured as survival, expansion or invasion under defined conditions.

A general causal design would compare tumour-conditioned and control-conditioned media on purified recipient biological cells, with matched biological cell numbers and viability, then wash and retest recipients to distinguish a persistent state from residual secreted factors. Ligand deletion in tumour biological cells, receptor deletion in recipients and recipient-specific rescue identify directionality. Add-back experiments, direct-contact versus barrier cultures and spatial lineage labels distinguish soluble signals, matrix effects and replacement by contaminating malignant biological cells. In vivo, use cell-type-specific interventions and immune-competent models where immune suppression is the proposed mechanism; a lymphocyte-deficient xenograft cannot establish the full immune interaction.

Importantly, supporting biological cells can also restrain disease. Depletion of alpha-smooth-muscle-actin-positive myofibroblasts in a pancreatic-cancer mouse model reduced fibrosis yet accelerated aggressive disease and immune suppression. The result shows that removing a conspicuous stromal component can eliminate protective functions as well as supportive ones.^[ref] The tumour's advantage emerges from particular reciprocal interactions, so the relevant question is which cell state and function are altered, rather than whether all surrounding normal biological cells are uniformly harmful.

New blood vessels in a healing wound arise chiefly by angiogenesis: sprouts grow from surviving blood vessels, unite into patent channels, and mature within the granulation tissue. Blood does not simply excavate permanent channels in a shapeless clot.

The initial wound contains a provisional extracellular matrix, including fibrin, with inflammatory biological cells and later fibroblasts. Local hypoxia and signals from injured tissue and inflammatory biological cells stimulate surviving endothelium. In modern molecular terms, vascular endothelial growth factor is an important stimulus. This molecular account explains the process today; it is not evidence that the examiner expected the named signalling molecule in 1867.^[ref]

The sequence is as follows:

This sequence separates growth of the cellular lining, formation of the channel, establishment of flow, and stabilization. These are different experimental observations, even though they overlap in time.^[ref]

An instructive anatomical investigation follows the wound at successive stages. Thin sections show solid sprouts, lumina lined by endothelium and their relation to the old blood vessels. Injection of a suitable casting material into the supplying blood vessels, followed by examination of the cast, reveals which channels are continuous with the circulation. The corneal wound example in the modern textbook uses resin injection and scanning electron microscopy of the resulting casts. Seeing an cord of endothelium and demonstrating a perfused loop therefore answer different questions.^[ref]

The essential repair process is sprouting, lumen formation, connection and maturation. The contrast with embryonic vasculogenesis, assembly from vascular precursors, helps define angiogenesis; it does not require assuming that every new blood vessel in an adult wound has an identical cellular history.

The rat dorsal air sac assay is an experimental bioassay of angiogenesis in which locally presented material is evaluated by the vascular response of tissue bordering a dorsal air space. It was used to test whether material derived from tumours could promote new blood vessels, connecting biochemical separation with a visible biological effect.

In the 1971 study by Judah Folkman, Ezio Merler, Charles Abernathy and Gretchen Williams, early experiments used membrane chambers containing live tumour cells. For testing separated material, the apparatus used silicone tubing with side openings covered by a short membrane sleeve. That sleeve acted as a diffusing wick, not as a filter. After 48 hours the vascular response was inspected with a stereomicroscope at $20\times$ magnification, followed by collection of sections for histology.^[ref]

The investigators graded vascular proliferation from 0 to 5+. Their illustrations show a wick without the active preparation as a negative control and progressively stronger vascular responses to active material.^[ref] The scientific question is whether the preparation alters the vascular response relative to an appropriate control. A visible response is not automatically a count of endothelial cells, a measured cell proliferation rate or evidence of functional perfusion.

An original scoring example shows why numerical coding must follow the measurement. Suppose one group receives grades 1, 1 and 4, and another receives 2, 2 and 2. Both arithmetic means are 2, although the response patterns differ. Moreover, the ordered relabeling $1\mapsto 1$, $2\mapsto 2$, $4\mapsto 10$ preserves the ranking but changes those means to 4 and 2. An ordered grade alone therefore does not define an interval scale on which differences have a fixed physical meaning. This example is not a reconstruction of the historical observations.

A useful contemporary comparison would specify the test material, solvent control, observation time and scoring rule, and keep the observer unaware of group assignment. Histology and explicit vessel measurements can help distinguish new vascular growth from dilation or local tissue disturbance. Such refinements answer additional measurement questions; this assay does not by itself identify a single angiogenic molecule or demonstrate a treatment effect in human cancer.

Vasculogenesis is formation of a vascular network by differentiation and assembly of endothelial precursors. It differs from angiogenesis, which expands or remodels vessels from an existing network.

Creating endothelial biological cells does not by itself create a functional blood vessel: cells must establish connections, polarity and an open lumen. Experiments on the developing mouse aorta connected endothelial polarization and junction remodeling to lumen formation.^[ref]